RESUMO

The belief that learning can be modulated by social context is mainly supported by high-level value-based learning studies. However, whether social context can even modulate low-level learning such as visual perceptual learning (VPL) is still unknown. Unlike traditional VPL studies in which participants were trained singly, here, we developed a novel dyadic VPL paradigm in which paired participants were trained with the same orientation discrimination task and could monitor each other's performance. We found that the social context (i.e., dyadic training) led to a greater behavioral performance improvement and a faster learning rate compared with the single training. Interestingly, the facilitating effects could be modulated by the performance difference between paired participants. Functional magnetic resonance imaging (fMRI) results showed that, compared with the single training, social cognition areas including bilateral parietal cortex and dorsolateral prefrontal cortex displayed a different activity pattern and enhanced functional connectivities to early visual cortex (EVC) during the dyadic training. Furthermore, the dyadic training resulted in more refined orientation representation in primary visual cortex (V1), which was closely associated with the greater behavioral performance improvement. Taken together, we demonstrate that the social context, learning with a partner, can remarkably augment the plasticity of low-level visual information process by means of reshaping the neural activities in EVC and social cognition areas, as well as their functional interplays.

Assuntos

Aprendizagem Espacial , Percepção Visual , Humanos , Cognição , Imageamento por Ressonância Magnética , Aprendizagem por Discriminação

RESUMO

In this work we present a novel algorithm for generating in-silico biomimetic models of a cortical bone microstructure towards manufacturing biomimetic bone via additive manufacturing. The software provides a tool for physicians or biomedical engineers to develop models of cortical bone that include the inherent complexity of the microstructure. The correspondence of the produced virtual prototypes with natural bone tissue was assessed experimentally employing Digital Light Processing (DLP) of a thermoset polymer resin to recreate healthy and osteoporotic bone tissue microstructure. The proposed tool was successfully implemented to develop cortical bone structure based on osteon density, cement line thickness, and the Haversian and Volkmann channels to produce a user-designated bone porosity that matches within values reported from literature for these types of tissues. Characterization of the specimens using a Scanning Electron Microscopy with Focused Ion Beam (SEM/FIB) and Computer Tomography (CT) revealed that the manufacturability of intricated virtual prototype is possible for scaled-up versions of the tissue. Modeling based on the density, inclination and size range of the osteon and Haversian and Volkmann´s canals granted the development of a dynamic in-silico porosity (13.37⁻21.49%) that matches with models of healthy and osteoporotic bone. Correspondence of the designed porosity with the manufactured assessment (5.79⁻16.16%) shows that the introduced methodology is a step towards the development of more refined and lifelike porous structures such as cortical bone. Further research is required for validation of the proposed methodology model of the real bone tissue and as a patient-specific customization tool of synthetic bone.

RESUMO

The VPl gene of enterovirus 71 (EV71) was synthesized, construct a recombinant plasmid pET15b/VP1 and expressed in E. coli BL21. The recombinant VP1 protein could specifically react with EV71-infected patient sera without the cross-reaction with serum antibodies of coxsackievirus A16 (CA16), A4, A5, B3 and B5 as well as echovirus 6. In acute and convalescent phases, IgM and IgG antibodies of 182 serum samples were detected by ELISA with recombinant VP1 protein as a coated antigen. The results showed that the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IgM antibodies in serum samples for the diagnosis of EV71 infection were 90.1, 98.4, 98.8 and 88.7%, respectively; similarly, those of IgG antibodies in serum samples were 82.4, 89.1, 91.5 and 78.1%, respectively. Five of 80 samples (6.25%) from CA16infected patients were detected positive by ELISA with recombinant VP1 protein in which indicated the cross reactions and 0 of 5 samples from patients infected with other enteroviruses including CA4, CA5, CB3, CB5 and echovirus 6. Therefore, the recombinant VP1 protein of EV7l may provide a theoretical reference for establishing an effective antibody screening of IgM for EV71-infected patients with clinically suspected hand, foot, and mouth disease (HFMD).

Assuntos

Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Anticorpos Antivirais/sangue , Proteínas do Capsídeo , Enterovirus Humano A/imunologia , Doença de Mão, Pé e Boca/diagnóstico , Clonagem Molecular , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/imunologia , Enterovirus Humano A/genética , Ensaio de Imunoadsorção Enzimática/métodos , Escherichia coli/genética , Expressão Gênica , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Valor Preditivo dos Testes , Proteínas Recombinantes , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Sensibilidade e Especificidade , Testes Sorológicos/métodos

RESUMO

The VPl gene of enterovirus 71 (EV71) was synthesized, construct a recombinant plasmid pET15b/VP1 and expressed in E. coli BL21. The recombinant VP1 protein could specifically react with EV71-infected patient sera without the cross-reaction with serum antibodies of coxsackievirus A16 (CA16), A4, A5, B3 and B5 as well as echovirus 6. In acute and convalescent phases, IgM and IgG antibodies of 182 serum samples were detected by ELISA with recombinant VP1 protein as a coated antigen. The results showed that the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IgM antibodies in serum samples for the diagnosis of EV71 infection were 90.1, 98.4, 98.8 and 88.7%, respectively; similarly, those of IgG antibodies in serum samples were 82.4, 89.1, 91.5 and 78.1%, respectively. Five of 80 samples (6.25%) from CA16-infected patients were detected positive by ELISA with recombinant VP1 protein in which indicated the cross reactions and 0 of 5 samples from patients infected with other enteroviruses including CA4, CA5, CB3, CB5 and echovirus 6. Therefore, the recombinant VP1 protein of EV7l may provide a theoretical reference for establishing an effective antibody screening of IgM for EV71-infected patients with clinically suspected hand, foot, and mouth disease (HFMD).

Assuntos

Anticorpos Antivirais/sangue , Proteínas do Capsídeo , Enterovirus Humano A/imunologia , Doença de Mão, Pé e Boca/diagnóstico , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/imunologia , Pré-Escolar , Clonagem Molecular , Enterovirus Humano A/genética , Ensaio de Imunoadsorção Enzimática/métodos , Escherichia coli/genética , Feminino , Expressão Gênica , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Lactente , Masculino , Valor Preditivo dos Testes , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Sensibilidade e Especificidade , Testes Sorológicos/métodos

RESUMO

The VPl gene of enterovirus 71 (EV71) was synthesized, construct a recombinant plasmid pET15b/VP1 and expressed in E. coli BL21. The recombinant VP1 protein could specifically react with EV71-infected patient sera without the cross-reaction with serum antibodies of coxsackievirus A16 (CA16), A4, A5, B3 and B5 as well as echovirus 6. In acute and convalescent phases, IgM and IgG antibodies of 182 serum samples were detected by ELISA with recombinant VP1 protein as a coated antigen. The results showed that the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IgM antibodies in serum samples for the diagnosis of EV71 infection were 90.1, 98.4, 98.8 and 88.7%, respectively; similarly, those of IgG antibodies in serum samples were 82.4, 89.1, 91.5 and 78.1%, respectively. Five of 80 samples (6.25%) from CA16infected patients were detected positive by ELISA with recombinant VP1 protein in which indicated the cross reactions and 0 of 5 samples from patients infected with other enteroviruses including CA4, CA5, CB3, CB5 and echovirus 6. Therefore, the recombinant VP1 protein of EV7l may provide a theoretical reference for establishing an effective antibody screening of IgM for EV71-infected patients with clinically suspected hand, foot, and mouth disease (HFMD).

RESUMO

The VPl gene of enterovirus 71 (EV71) was synthesized, construct a recombinant plasmid pET15b/VP1 and expressed in E. coli BL21. The recombinant VP1 protein could specifically react with EV71-infected patient sera without the cross-reaction with serum antibodies of coxsackievirus A16 (CA16), A4, A5, B3 and B5 as well as echovirus 6. In acute and convalescent phases, IgM and IgG antibodies of 182 serum samples were detected by ELISA with recombinant VP1 protein as a coated antigen. The results showed that the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IgM antibodies in serum samples for the diagnosis of EV71 infection were 90.1, 98.4, 98.8 and 88.7%, respectively; similarly, those of IgG antibodies in serum samples were 82.4, 89.1, 91.5 and 78.1%, respectively. Five of 80 samples (6.25%) from CA16infected patients were detected positive by ELISA with recombinant VP1 protein in which indicated the cross reactions and 0 of 5 samples from patients infected with other enteroviruses including CA4, CA5, CB3, CB5 and echovirus 6. Therefore, the recombinant VP1 protein of EV7l may provide a theoretical reference for establishing an effective antibody screening of IgM for EV71-infected patients with clinically suspected hand, foot, and mouth disease (HFMD).